These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36980184)

  • 1. Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker.
    Martínez-Bosch N; Vilariño N; Alameda F; Mojal S; Arumí-Uria M; Carrato C; Aldecoa I; Ribalta T; Vidal N; Bellosillo B; Menéndez S; Del Barco S; Gallego O; Pineda E; López-Martos R; Hernández A; Mesia C; Esteve-Codina A; de la Iglesia N; Balañá C; Martínez-García M; Navarro P
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
    Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
    Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas.
    Engler JR; Robinson AE; Smirnov I; Hodgson JG; Berger MS; Gupta N; James CD; Molinaro A; Phillips JJ
    PLoS One; 2012; 7(8):e43339. PubMed ID: 22937035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of galectin-1 expression in non-small cell lung cancer patients.
    Carlini MJ; Roitman P; Nuñez M; Pallotta MG; Boggio G; Smith D; Salatino M; Joffé ED; Rabinovich GA; Puricelli LI
    Lung Cancer; 2014 Apr; 84(1):73-8. PubMed ID: 24560493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma.
    Santosh V; Arivazhagan A; Sreekanthreddy P; Srinivasan H; Thota B; Srividya MR; Vrinda M; Sridevi S; Shailaja BC; Samuel C; Prasanna KV; Thennarasu K; Balasubramaniam A; Chandramouli BA; Hegde AS; Somasundaram K; Kondaiah P; Rao MR
    Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1399-408. PubMed ID: 20501753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
    Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
    Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes.
    Patil V; Mahalingam K
    Gene; 2019 Feb; 685():85-95. PubMed ID: 30401645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy.
    Van Woensel M; Mathivet T; Wauthoz N; Rosière R; Garg AD; Agostinis P; Mathieu V; Kiss R; Lefranc F; Boon L; Belmans J; Van Gool SW; Gerhardt H; Amighi K; De Vleeschouwer S
    Sci Rep; 2017 Apr; 7(1):1217. PubMed ID: 28450700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of immunologic subtype and prognosis of GBM based on TNFSF14 and immune checkpoint gene expression profiling.
    Long S; Li M; Liu J; Yang Y; Li G
    Aging (Albany NY); 2020 Apr; 12(8):7112-7128. PubMed ID: 32310827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy.
    Carrato C; Alameda F; Esteve-Codina A; Pineda E; Arpí O; Martinez-García M; Mallo M; Gut M; Lopez-Martos R; Barco SD; Ribalta T; Capellades J; Puig J; Gallego O; Mesia C; Muñoz-Marmol AM; Archilla I; Arumí M; Blanc JM; Bellosillo B; Menendez S; Esteve A; Bagué S; Hernandez A; Craven-Bartle J; Fuentes R; Vidal N; Aldecoa I; Iglesia N; Balana C
    Clin Cancer Res; 2020 Dec; 26(24):6600-6609. PubMed ID: 32998960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galectins-1, -3, and -7 Are Prognostic Markers for Survival of Ovarian Cancer Patients.
    Schulz H; Schmoeckel E; Kuhn C; Hofmann S; Mayr D; Mahner S; Jeschke U
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28594391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of galectin-1 in migration and invasion of human glioblastoma multiforme cell lines.
    Jung TY; Jung S; Ryu HH; Jeong YI; Jin YH; Jin SG; Kim IY; Kang SS; Kim HS
    J Neurosurg; 2008 Aug; 109(2):273-84. PubMed ID: 18671640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact.
    Sathyan P; Zinn PO; Marisetty AL; Liu B; Kamal MM; Singh SK; Bady P; Lu L; Wani KM; Veo BL; Gumin J; Kassem DH; Robinson F; Weng C; Baladandayuthapani V; Suki D; Colman H; Bhat KP; Sulman EP; Aldape K; Colen RR; Verhaak RG; Lu Z; Fuller GN; Huang S; Lang FF; Sawaya R; Hegi M; Majumder S
    J Neurosci; 2015 Nov; 35(45):15097-112. PubMed ID: 26558781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galectin signatures contribute to the heterogeneity of breast cancer and provide new prognostic information and therapeutic targets.
    Grosset AA; Labrie M; Vladoiu MC; Yousef EM; Gaboury L; St-Pierre Y
    Oncotarget; 2016 Apr; 7(14):18183-203. PubMed ID: 26933916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Ki-67 index overexpression in IDH wild type glioblastoma a predictor of shorter Progression Free survival? A clinical and Molecular analytic investigation.
    Armocida D; Frati A; Salvati M; Santoro A; Pesce A
    Clin Neurol Neurosurg; 2020 Nov; 198():106126. PubMed ID: 32861131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value.
    Reddy PS; Umesh S; Thota B; Tandon A; Pandey P; Hegde AS; Balasubramaniam A; Chandramouli BA; Santosh V; Rao MR; Kondaiah P; Somasundaram K
    Cancer Biol Ther; 2008 May; 7(5):663-8. PubMed ID: 18728403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cell immune regulator 1 is a prognostic marker associated with immune infiltration in glioblastoma multiforme.
    Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
    Oncol Lett; 2021 Apr; 21(4):252. PubMed ID: 33664816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and prognostic significance of TCTN1 in human glioblastoma.
    Meng D; Chen Y; Zhao Y; Wang J; Yun D; Yang S; Chen J; Chen H; Lu D
    J Transl Med; 2014 Oct; 12():288. PubMed ID: 25304031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 expression and prognostic impact in glioblastoma.
    Nduom EK; Wei J; Yaghi NK; Huang N; Kong LY; Gabrusiewicz K; Ling X; Zhou S; Ivan C; Chen JQ; Burks JK; Fuller GN; Calin GA; Conrad CA; Creasy C; Ritthipichai K; Radvanyi L; Heimberger AB
    Neuro Oncol; 2016 Feb; 18(2):195-205. PubMed ID: 26323609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel prognostic targets in glioblastoma using bioinformatics analysis.
    Yin X; Wu Q; Hao Z; Chen L
    Biomed Eng Online; 2022 Apr; 21(1):26. PubMed ID: 35436915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.